A phase II study of triapine in combination with gemcitabine (G) in patients (pts) with unresectable or metastatic pancreatic cancer (PC).

E. Greeno,H. Kindler,M. Peeters,R. Trowbridge,G. Chong,J. Valle,B. Johnson,E. Allain,H. Burris

DOI: https://doi.org/10.1200/jco.2006.24.18_suppl.4123

IF: 45.3

2006-06-20

Journal of Clinical Oncology

Abstract:4123 Background: Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone [T]) is a small molecule that inhibits ribonucleotide reductase at a site distinct from G. In tumor cell lines, pre-exposure to T enhances G uptake and DNA incorporation, and yields synergistic cytotoxicity. A phase I trial of T + G showed that the combination was well-tolerated and produced T serum concentrations sufficient to modulate G activity in vitro (Ca Chemother Pharmacol, 2004). METHODS We conducted a phase II trial of T + G in advanced PC pts at 7 centers. Eligible pts were untreated, had measurable disease and ECOG PS 0-2. T was given by 4-hr infusion followed by G 1000 mg/m2 on days 1, 8, and 15 of a 4-week schedule. Since preclinical studies showed longer exposure of T maximized synergy between the agents, the protocol was amended to administer T over 24 hrs continuously (CI) prior to G. Pts were assessed for response q 2 cycles and retreated to progression or toxicity. RESULTS Sixty pts (median age 62, range 37-88) were treated with T by 4-hr infusion (median 4 cycles, range 1-18). Pt characteristics included M:F 39/21; PS 0/1/2 = 25 (42%)/34 (57%)/1 (2%); metastatic/locally advanced 72/28%. Eight (15%) patients achieved PR; and 32 (60%) had stable disease. Median survival was 8 mos; 13% are alive at 1 yr. The next 6 pts (median age 54, range 50-69, M/F: 3/3) received T at a fixed dose of 400mg CI + G. Two pts were evaluable for response; 1 pt had PD, 1 pt is on treatment after 14 cycles. Due to excessive myelosuppression the dose of T CI was reduced to 105 mg/m2. Of 7 pts (median age 60, range 34-73) treated, 2 had PD, 1 was unevaluable, and 4 remain on tx. T toxicity included hypotension, hypoxia, rash and dyspnea in < 10% of pts. In the 2 CI groups (N=13), the only toxicity attributed to T was excessive myelosuppression, requiring G dose reduction in all pts. Survival data on CI pts pending. CONCLUSIONS T + G shows activity in PC. As predicted by preclinical studies, prolonged exposure (CI) enhances biological effect of T + G evidenced by increased myelosuppression without additional toxicities. Further studies are warranted to define the optimal dose of T CI with G. [Table: see text].